NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 07 04:00PM ET
0.8817
Dollar change
+0.0017
Percentage change
0.19
%
Index- P/E- EPS (ttm)-0.29 Insider Own72.09% Shs Outstand36.17M Perf Week0.08%
Market Cap31.89M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.10M Perf Month-10.94%
Enterprise Value31.47M PEG- EPS next Q-0.11 Inst Own1.70% Short Float2.51% Perf Quarter-6.20%
Income-10.48M P/S- EPS this Y- Inst Trans109.18% Short Ratio1.24 Perf Half Y-26.53%
Sales0.00M P/B- EPS next Y- ROA-189.25% Short Interest0.25M Perf YTD-26.53%
Book/sh-0.05 P/C75.93 EPS next 5Y- ROE-314.60% 52W High3.23 -72.70% Perf Year-19.11%
Cash/sh0.01 P/FCF- EPS past 3/5Y-152.25% - ROIC- 52W Low0.63 39.95% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.76% 10.75% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-57.12% Oper. Margin- ATR (14)0.10 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.22 Sales Y/Y TTM- Profit Margin- RSI (14)44.31 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.22 EPS Q/Q-340.91% SMA20-6.83% Beta0.36 Target Price16.00
Payout- Debt/Eq- Sales Q/Q- SMA50-11.38% Rel Volume0.19 Prev Close0.88
Employees- LT Debt/Eq- EarningsMay 28 SMA200-13.60% Avg Volume204.18K Price0.88
IPOSep 14, 2021 Option/ShortNo / Yes EPS/Sales Surpr.0.00% - Trades Volume38,839 Change0.19%
Jun-05-25 08:00AM
Jun-03-25 08:00AM
May-29-25 11:15PM
08:01AM
Mar-05-25 08:00AM
08:55AM Loading…
Feb-22-25 08:55AM
Feb-21-25 08:30AM
Feb-19-25 04:46PM
Sep-27-24 12:00PM
Aug-14-24 12:00PM
Aug-02-24 07:34AM
May-20-24 10:52AM
Sep-29-23 10:34AM
Sep-18-23 05:00PM
Aug-18-23 04:30PM
04:30PM Loading…
Jul-18-23 04:30PM
Jul-12-23 07:00AM
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.